A Study Into the Effect of Seprafilm in Open Total Thyroidectomy

Status Terminated

Clinical Trial Summary

The investigators intend to determine the role of Seprafilm, a popular anti-adhesive agent in minimising internal adhesion formation in the neck after thyroid surgery and therefore reduce swallowing discomfort experienced by patients after surgery.

Clinical Trial Description

Thyroid surgery not only constitutes one of the main pillars in the treatment of thyroid cancers, but is also employed in the management of symptomatic goitres. Occasionally, it is mandated in patients with thyrotoxicosis refractory to medical therapy. While thyroid surgery can be performed with low risks such that patients rarely have to stay beyond three days in hospital, the track record of thyroid surgery is somewhat blemished by the unfortunate side effects associated with the neck scarring after thyroid surgery. Not uncommonly, patients experience discomfort in the neck region after thyroid surgery; in the extreme of cases, patients may even complain of a lifelong pulling sensation in the neck area during eating.

The anti-adhesive properties of Seprafilm are well established in animal studies and affirmed by clinical observations in abdominal surgeries that utilize this material. Thus, Seprafilm is routinely used in instances when a surgeon foresees a need to perform abdominal surgery on the same patient in future, or during the fashioning of a temporary stoma. The safety profile of Seprafilm in thyroidectomy has also been shown by a recent study conducted by a group of clinicians in Seoul.

We postulate that the application of Seprafilm to the surgical wound towards the end of a thyroidectomy significantly reduces internal adhesion formation in the neck region. By achieving this objective, we hope to improve patients' satisfaction with thyroid surgery in terms of ease of swallowing after surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01865838
Study type	Interventional
Source	National Cancer Centre, Singapore
Contact
Status	Terminated
Phase	N/A
Start date	May 2013
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02658513` - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn	`NCT01707056` - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma	N/A
Completed	`NCT00215605` - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies	Phase 1
Completed	`NCT06439745` - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Terminated	`NCT04327999` - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System	Phase 2
Completed	`NCT02194920` - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function	N/A
Enrolling by invitation	`NCT06095362` - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW	Phase 1
Not yet recruiting	`NCT05949424` - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults	Phase 4
Active, not recruiting	`NCT02145143` - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study	N/A
Recruiting	`NCT00749697` - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases	N/A
Enrolling by invitation	`NCT04411290` - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed	`NCT01813136` - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma	Phase 2
Recruiting	`NCT05668962` - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Phase 2
Active, not recruiting	`NCT02185560` - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed	`NCT04462471` - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers	Phase 1
Completed	`NCT01433809` - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm	N/A
Recruiting	`NCT00929318` - Influence of Thyroid Hormones on the Woundhealing Process	N/A
Completed	`NCT05178186` - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer	N/A
Completed	`NCT02773667` - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Completed	`NCT01013597` - Trial of LBH589 in Metastatic Thyroid Cancer	Phase 2